NASDAQ:ATRC - AtriCure Stock Price, Forecast & News

AtriCure trades on the NASDAQ under the ticker symbol "ATRC."

AtriCure Inc. (NASDAQ:ATRC) posted its earnings results on Wednesday, October, 30th. The medical device company reported ($0.25) EPS for the quarter, beating the Zacks' consensus estimate of ($0.28) by $0.03. The medical device company had revenue of $56.60 million for the quarter, compared to analysts' expectations of $55.12 million. AtriCure had a negative return on equity of 13.59% and a negative net margin of 10.13%. The company's quarterly revenue was up 13.4% on a year-over-year basis. During the same period last year, the firm earned ($0.24) EPS. View AtriCure's Earnings History.

AtriCure is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for AtriCure.

AtriCure updated its fourth quarter 2019 Pre-Market earnings guidance on Monday, January, 13th. The company provided EPS guidance of for the period. The company issued revenue guidance of $61.3-61.3 million, compared to the consensus revenue estimate of $59.24 million.

5 equities research analysts have issued 12 month target prices for AtriCure's stock. Their forecasts range from $30.00 to $40.00. On average, they expect AtriCure's stock price to reach $36.20 in the next twelve months. This suggests that the stock has a possible downside of 5.4%. View Analyst Price Targets for AtriCure.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AtriCure in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for AtriCure.

Headlines about ATRC stock have been trending positive this week, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. AtriCure earned a news impact score of 3.0 on InfoTrie's scale. They also gave news articles about the medical device company a news buzz of 5.0 out of 10, indicating that recent media coverage is somewhat likely to have an impact on the company's share price in the next few days. View News Stories for AtriCure.

Some companies that are related to AtriCure include Medtronic (MDT), Abbott Laboratories (ABT), Stryker (SYK), Becton Dickinson and (BDX), Intuitive Surgical (ISRG), Boston Scientific (BSX), Edwards Lifesciences (EW), Baxter International (BAX), IDEXX Laboratories (IDXX), ResMed (RMD), DexCom (DXCM), Teleflex (TFX), Hologic (HOLX), Varian Medical Systems (VAR) and Steris (STE).

Based on aggregate information from My MarketBeat watchlists, some companies that other AtriCure investors own include AbbVie (ABBV), Amgen (AMGN), Gilead Sciences (GILD), Neurocrine Biosciences (NBIX), Enterprise Products Partners (EPD), Cellectis (CLLS), Abbott Laboratories (ABT), Alnylam Pharmaceuticals (ALNY), bluebird bio (BLUE) and DexCom (DXCM).

AtriCure's stock is owned by many different of institutional and retail investors. Top institutional investors include Peregrine Capital Management LLC (1.93%). Company insiders that own AtriCure stock include Douglas J Seith, Elizabeth D Krell, Justin J Noznesky, M Andrew Wade, Mark A Collar, Michael H Carrel and Regina E Groves. View Institutional Ownership Trends for AtriCure.

ATRC stock was sold by a variety of institutional investors in the last quarter, including Peregrine Capital Management LLC. Company insiders that have sold AtriCure company stock in the last year include Douglas J Seith, Justin J Noznesky, M Andrew Wade, Mark A Collar and Michael H Carrel. View Insider Buying and Selling for AtriCure.

Shares of ATRC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ATRC stock can currently be purchased for approximately $38.25.

AtriCure has a market capitalization of $1.51 billion and generates $201.63 million in revenue each year. The medical device company earns $-21,140,000.00 in net income (profit) each year or ($0.94) on an earnings per share basis. AtriCure employs 620 workers across the globe.View Additional Information About AtriCure.

The official website for AtriCure is http://www.atricure.com/.

AtriCure's mailing address is 7555 INNOVATION WAY, MASON OH, 45040. The medical device company can be reached via phone at 513-755-4100.